Oliver Bayliss, Norma Jean Nowak

Apr 14, 2003

Premium

BioWisdom has appointed Oliver Bayliss as director of sales and business development. Bayliss, who has over ten years of sales experience at Viaken Systems, Accelrys, GCG, Oxford Molecular, and DNAStar, will spearhead the expansion of the company’s worldwide direct sales operation. He will also develop and manage BioWisdom’s channel strategies to deliver the company’s ontologies through a range of third-party tools.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

From Tusk to Cartel

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

The Same Genes Keep Getting Asked to Prom

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

Keep Them in the Know

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

This Week in Nature

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu